BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12549959)

  • 1. Tamoxifen for prevention of breast cancer.
    Cersosimo RJ
    Ann Pharmacother; 2003 Feb; 37(2):268-73. PubMed ID: 12549959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
    Brewster AM; Christo DK; Lai H; Helzlsouer K
    Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the main outcomes in breast-cancer prevention trials.
    Cuzick J; Powles T; Veronesi U; Forbes J; Edwards R; Ashley S; Boyle P
    Lancet; 2003 Jan; 361(9354):296-300. PubMed ID: 12559863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should tamoxifen be used in breast cancer prevention?
    Kramer R; Brown P
    Drug Saf; 2004; 27(13):979-89. PubMed ID: 15471505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
    Crowell EB; Jubelirer SJ
    W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors for the treatment and prevention of breast cancer.
    Kalidas M; Brown P
    Clin Breast Cancer; 2005 Apr; 6(1):27-37. PubMed ID: 15899070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
    Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
    J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs.
    Nease RF; Ross JM
    Am J Med; 1995 Aug; 99(2):180-9. PubMed ID: 7625423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tamoxifen controversy.
    Crabbe WW
    Oncol Nurs Forum; 1996 Jun; 23(5):761-6. PubMed ID: 8792346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of breast cancer.
    Dalton RR; Kallab AM
    South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on breast cancer prevention.
    Rastogi P; Vogel VG
    Oncology (Williston Park); 2003 Jun; 17(6):799-805; discussion 808-10, 813. PubMed ID: 12846124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.